Alvotech SDB
Research Alvotech SDB (ALVO-SDB) on Bullrun: market cap SEK 14.05B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALVO-SDB
- ExchangeST
- CountryLuxembourg
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencySEK
- Market capSEK 14.05B
- Financial periodQ1 2026
- RevenueUSD 105.87M
- Net incomeUSD 1.03M
- Free cash flow-USD 106.62M
- Gross margin56.5%
Valuation Snapshot
latest market cap is SEK 14.05B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 586.32M | USD 27.92M | -USD 146.33M | 59.8% | n/a | USD 172.36M | USD 1.45B | -USD 284.49M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | SEK 14.05B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Alvotech SDB
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Alvotech SDB's market cap?
Alvotech SDB's market capitalization is SEK 14.05B.
What does Alvotech SDB do?
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.